Last reviewed · How we verify
Standard-dose intravenous tenecteplase
Tenecteplase is a tissue plasminogen activator that works by catalyzing the conversion of plasminogen to plasmin, resulting in the breakdown of blood clots.
Tenecteplase is a tissue plasminogen activator that works by catalyzing the conversion of plasminogen to plasmin, resulting in the breakdown of blood clots. Used for Acute ischemic stroke.
At a glance
| Generic name | Standard-dose intravenous tenecteplase |
|---|---|
| Sponsor | The George Institute |
| Drug class | tissue plasminogen activator |
| Target | tPA |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This process is crucial for the treatment of acute ischemic stroke, as it helps to restore blood flow to the affected area of the brain. Tenecteplase is a recombinant form of tPA, which has a higher specificity and lower risk of bleeding compared to its natural counterpart.
Approved indications
- Acute ischemic stroke
Common side effects
- Hemorrhage
- Allergic reactions
Key clinical trials
- Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients (PHASE4)
- Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours (PHASE4)
- Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours (PHASE3)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging (PHASE3)
- Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke
- Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke (PHASE3)
- Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard-dose intravenous tenecteplase CI brief — competitive landscape report
- Standard-dose intravenous tenecteplase updates RSS · CI watch RSS
- The George Institute portfolio CI